Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dewi Vernerey

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
Journal of the National Cancer Institute|August 20, 2025
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter studyAziz Zaanan, Elisabeth Sophie Bergen, Ludovic Evesque, et al.
International Journal of Cancer|November 13, 2020
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohortThomas Aparicio, Magali Svrcek, Julie Henriques, et al.
Annals of Intensive Care|March 9, 2022
Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumoniaGuillaume Eberst, Fréderic Claudé, Lucie Laurent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2022
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II StudyThierry André, David Tougeron, Guillaume Piessen, et al.
Ebiomedicine|May 17, 2025
Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastasesJulien Viot, Romain Loyon, Nawfel Adib, et al.
International Journal of Cancer|January 9, 2020
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patientsThomas Aparicio, Julie Henriques, Sylvain Manfredi, et al.
JHEP Reports : Innovation in Hepatology|February 3, 2025
First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohortNicolas Adamus, Julien Edeline, Julie Henriques, et al.
Frontiers in Oncology|August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL StudyMagali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
Bulletin Du Cancer|February 15, 2020
[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]Romain Cohen, Thomas Pudlarz, Marie-Line Garcia-Larnicol, et al.
The New England Journal of Medicine|September 27, 2013
Complement-binding anti-HLA antibodies and kidney-allograft survivalAlexandre Loupy, Carmen Lefaucheur, Dewi Vernerey, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Journal of the National Cancer Institute|August 20, 2025
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter studyAziz Zaanan, Elisabeth Sophie Bergen, Ludovic Evesque, et al.
International Journal of Cancer|November 13, 2020
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohortThomas Aparicio, Magali Svrcek, Julie Henriques, et al.
Annals of Intensive Care|March 9, 2022
Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumoniaGuillaume Eberst, Fréderic Claudé, Lucie Laurent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2022
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II StudyThierry André, David Tougeron, Guillaume Piessen, et al.
Ebiomedicine|May 17, 2025
Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastasesJulien Viot, Romain Loyon, Nawfel Adib, et al.
International Journal of Cancer|January 9, 2020
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patientsThomas Aparicio, Julie Henriques, Sylvain Manfredi, et al.
JHEP Reports : Innovation in Hepatology|February 3, 2025
First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohortNicolas Adamus, Julien Edeline, Julie Henriques, et al.
Frontiers in Oncology|August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL StudyMagali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
Bulletin Du Cancer|February 15, 2020
[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]Romain Cohen, Thomas Pudlarz, Marie-Line Garcia-Larnicol, et al.
The New England Journal of Medicine|September 27, 2013
Complement-binding anti-HLA antibodies and kidney-allograft survivalAlexandre Loupy, Carmen Lefaucheur, Dewi Vernerey, et al.
Pageof 16